Shenzhen Cell Valley was approved as a high-growth enterprise of "Jurong Leading Talents" (Class D) in the biomedical field of Pingshan District in 2023
Recently, Shenzhen Pingshan District Science and Technology Innovation Bureau officially announced the "2023 year Pingshan District biomedical field" Julong Leading talents "(D class) high-growth enterprise uation result Announcement", Shenzhen Cell Valley with its excellent innovation ability and huge market potential, Successfully approved by Pingshan District biomedical field 2023 "Jurong Leading talents" (D class) high-growth enterprises. After the approval, the company will have 2 independent recommendation places every year to declare "Jurong Leading talents" category D.

As the key development area of Shenzhen's biomedical industry, Pingshan District has gathered many excellent biomedical enterprises. In order to promote the high-quality development of the industry, Pingshan District has formulated a series of talent policies to attract and cultivate more high-quality talents in the industry and inject a steady stream of innovative vitality into the industrial development.
The honor won by Shenzhen Cell Valley is not only an affirmation of the company's own innovation ability and market potential, but also a recognition of the important role played in promoting the cultivation of talents in the biomedical industry in Pingshan District. As an important member of the biomedicine strategic emerging industry and the cell and gene future industry in Shenzhen's "20+8" industrial cluster, Shenzhen Cell Valley will continue to exert its technological advantages and innovation capabilities, increase R&D investment, accelerate the transformation of innovation achievements, and contribute to the upgrading and development of the biomedicine industry in Pingshan District. At the same time, the company will also actively respond to the talent policy of Pingshan District, attract and train more outstanding talents, and jointly promote the prosperity and development of the biomedical industry.